MedPath

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

59

Active:5
Completed:33

Trial Phases

4 Phases

Phase 1:37
Phase 2:10
Phase 3:7
+1 more phases

Drug Approvals

1

FDA:1

Drug Approvals

Elepsia XR

Approval Date
Jan 6, 2021
FDA

Clinical Trials

Distribution across different clinical trial phases (57 trials with phase data)• Click on a phase to view related trials

Phase 1
37 (64.9%)
Phase 2
10 (17.5%)
Phase 3
7 (12.3%)
Not Applicable
3 (5.3%)

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

Not Applicable
Not yet recruiting
Conditions
Advanced Solid Tumors
Interventions
Biological: Dose level (DL)1
Biological: DL2
Biological: DL4
Biological: DL5
First Posted Date
2025-06-27
Last Posted Date
2025-07-04
Lead Sponsor
Sun Pharma Advanced Research Company Limited
Target Recruit Count
177
Registration Number
NCT07042100
Locations
🇮🇳

SPARC Investigative Site, Delhi, New Delhi, India

A Study in Patients With Advanced Breast Cancer

Phase 1
Terminated
Conditions
HER2-negative Breast Cancer
Advanced Breast Cancer
Hormone Receptor-positive Breast Cancer
Interventions
Drug: Part 1
Drug: Part 2
Drug: Part 3
First Posted Date
2021-06-28
Last Posted Date
2023-05-22
Lead Sponsor
Sun Pharma Advanced Research Company Limited
Target Recruit Count
9
Registration Number
NCT04942054
Locations
🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

🇺🇸

The University of Chicago, Chicago, Illinois, United States

🇮🇳

HealthCare Global Enterprises Ltd, Bangalore, Karnataka, India

and more 3 locations

To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer

Phase 1
Withdrawn
Conditions
Locally Recurrent Cancer
Metastatic Breast Cancer
Interventions
Drug: PICS (Reconstitution Method 1 or 2)
First Posted Date
2020-04-02
Last Posted Date
2020-06-01
Lead Sponsor
Sun Pharma Advanced Research Company Limited
Registration Number
NCT04332549
Locations
🇮🇳

SPARC Site 12, Visakhapatnam, Andhra Pradesh, India

🇮🇳

SPARC Site 21, Ahmadabad, Gujarat, India

🇮🇳

SPARC Site 22, Sūrat, Gujarat, India

and more 19 locations

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects

Phase 1
Completed
Conditions
Healthy Volunteer Study
Interventions
Drug: matching placebo
First Posted Date
2020-01-27
Last Posted Date
2023-04-21
Lead Sponsor
Sun Pharma Advanced Research Company Limited
Target Recruit Count
140
Registration Number
NCT04242953
Locations
🇺🇸

AXIS Clinicals, Dilworth, Minnesota, United States

🇺🇸

BioPharma Services USA Inc., Creve Coeur, Missouri, United States

🇨🇦

BioPharma Services Inc., Toronto, Ontario, Canada

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Phase 2
Terminated
Conditions
Early Parkinson Disease
Interventions
Other: placebo
First Posted Date
2018-08-31
Last Posted Date
2024-07-18
Lead Sponsor
Sun Pharma Advanced Research Company Limited
Target Recruit Count
513
Registration Number
NCT03655236
Locations
🇺🇸

Xenoscience Inc. - 21st Century Neurology, Phoenix, Arizona, United States

🇺🇸

University of Arkansas for Medical Sciences (UAMS) - Movement Disorders Clinic, Little Rock, Arkansas, United States

🇺🇸

Keck Hospital of USC, Los Angeles, California, United States

and more 74 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath